OV101 Regimen 1 ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
201 | アンジェルマン症候群 | 1 |
201. アンジェルマン症候群
臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02996305 (ClinicalTrials.gov) | January 2016 | 2/12/2016 | A Study in Adults and Adolescents With Angelman Syndrome | A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol | Angelman Syndrome | Drug: OV101 Regimen 1;Drug: OV101 regimen 2;Other: Placebo | Ovid Therapeutics Inc. | NULL | Completed | 13 Years | 49 Years | All | 88 | Phase 2 | United States;Israel |